GPR65 Modulators Exploit Acidic Tumour pH for Selective Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective modulators for GPR65, a receptor implicated in both tumour evasion and autoimmune diseases, necessitating the development of new compounds to target this pathway for therapeutic intervention.
Innovation Solution
Development of specific compounds, such as those described in formulae (I), (Ig), and (Ih), which modulate GPR65, potentially altering its activity to impact immune responses and tumour microenvironments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GPR65 is activated by acidic extracellular pH in tumour microenvironment, then cytoplasmic cAMP increases leading to ICER transcription, but this suppresses TNFα secretion and promotes tumour-permissive phenotype
Solution Approach 1:
The patent converts the harmful acidic microenvironment created by tumour glycolysis into a beneficial therapeutic opportunity by designing pH-sensitive prodrugs that are activated specifically in the acidic tumour microenvironment. The acidic pH that normally promotes tumour evasion is exploited to trigger activation of immune-modulating agents that reverse the suppressive phenotype.
Solution Approach 2:
The patent employs pH as a critical parameter to control drug activation and delivery. By designing compounds with pH-sensitive chemical bonds or structures that break or transform at acidic pH values typical of tumour microenvironments, the system achieves selective activation only in the pathological condition, converting the harmful parameter into a control mechanism for therapeutic effect.
2Reliability
If GPR65 signalling is enhanced to reduce tumour-permissive phenotype, then immune detection improves, but off-target effects on normal tissues may occur
Solution Approach 1:
The patent incorporates targeting moieties or ligands that pre-position the prodrug or activate it preferentially at the tumour site before systemic distribution effects can cause off-target toxicity. The acidic pH-triggered activation occurs preliminary to any potential harmful effects on normal tissues, ensuring spatial selectivity.
Solution Approach 2:
The patent uses pH-sensitive chemical intermediates or carrier systems that mediate between the systemic administration and the local tumour site. These intermediaries remain inactive in neutral pH conditions of normal tissues but transform into active immune-modulating agents in the acidic tumour microenvironment, preventing off-target effects.
3Adaptability or versatility
If new GPR65 modulators are developed for therapeutic intervention, then treatment options for cancer and autoimmune diseases expand, but drug development complexity and time increase
Solution Approach 1:
The patent designs a versatile prodrug platform that can deliver multiple different active agents through a single activation mechanism (pH-sensitive bond cleavage). This universal delivery system can be adapted to various GPR65 modulators with different therapeutic indications, reducing the need to develop separate delivery systems for each compound and simplifying the overall development complexity.
Data Source
AI summary
The present invention relates to compounds of formula (I) as GPR65 modulators for the treatment of a proliferative disorder, such as e.g. cancer, an immune disorder, asthma, chronic obstructive pulmonary disease (CORD) or acute respiratory distress syndrome (ARDS). Preferred compounds are e.g. N-(Pyridin-2-yl)-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[c]pyridine-10-carboxamide derivatives and similar compounds, such as e.g. (5R,8S)—N-(4-chloro-5-(trifluoromethyl)pyridin-2-yl)-1-fluoro-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[c]pyridine-10-carboxamide (compound 1)